The Angelman Syndrome Foundation advances awareness and treatment of Angelman syndrome, a neurodevelopmental disorder caused by deficiency of the ubiquitin protein ligase UBE3A in the brain. The foundation advances this mission through education, research, and support for individuals with Angelman syndrome, their families, and other concerned parties.
As part of this mission, the foundation is accepting proposals for pre-clinical, translational, and clinical research projects that investigate any or all aspects of Angelman syndrome. Priority will be given to pilot projects that test new ideas about pathogenesis and therapeutics of Angelman syndrome, translational research, and clinical research studies. Of particular interest to ASF are studies related to communication, behavioral issues, and identification of issues and treatments that impact the daily life of people with Angelman syndrome and their families.
One- or two-year grants will be awarded for various amounts of up to $100,000 per year.
Researchers from all countries are encouraged to apply.
For complete program guidelines and application instructions, see the Angelman Syndrome Foundation's website.